PMC Stock Drops as Pharmedic Eye Drop Recall Ordered by Drug Administration

Overview

The Drug Administration of Vietnam (Ministry of Health) ordered a nationwide recall of a Pharmedic (HNX: PMC) eye drop batch on May 14, 2026, due to failure in clarity quality standards. PMC stock declined nearly 1% on May 15, recovering from an intraday drop of 10%, as the company attributed the issue to supply chain operations rather than manufacturing expertise.

Key Facts

• The recall covers lot number 10370725 of Natri clorid 0.9% eye drops, registration number 893100060724, manufactured on July 14, 2025, with expiry January 14, 2028.
• The violation is classified as level 3 (moderate risk) under Vietnamese regulations.
• All distributors and healthcare facilities must halt sales and use of the batch, with recall results due by May 29, 2026.
• PMC was previously fined VND 70 million on January 21, 2026, for a similar quality violation.
• PMC stock closed at VND 138,500 on May 15, down 0.72%, with trading volume of only 1,600 shares.
• The stock had fallen as much as 10% intraday before recovering.
• PMC reported net profit of nearly VND 23 billion in Q1 2026, with annual net profit stable around VND 80-84 billion in recent years.

What Happened

On May 14, 2026, the Drug Administration of Vietnam issued a nationwide recall order for a batch of Natri clorid 0.9% eye drops manufactured by Pharmedic (PMC). The product failed the clarity specification test, triggering a level 3 violation. The recall requires all business establishments and healthcare facilities to immediately stop distributing, supplying, and using the affected lot, and to return products to the distributor. Results must be reported by May 29, 2026.

In response to shareholder concerns at a recent general meeting, PMC management stated the incident was an unintended supply chain issue, not a manufacturing defect, and that corrective actions had been taken. The company had previously been fined VND 70 million in January 2026 for a similar quality non-compliance.

Market Context

PMC shares on HNX closed at VND 138,500 on May 15, down 0.72% from the previous session, after recovering from an intraday drop of nearly 10%. Trading volume remained extremely low at 1,600 shares, consistent with the stock’s thin liquidity pattern. PMC has been in a downtrend since peaking above VND 180,000 in December 2025, despite stable earnings. The stock’s average daily volume is only about 2,000 shares, indicating limited institutional interest.

Strategic Significance

The recall, while isolated to one batch, raises questions about PMC’s quality control processes, especially given the prior fine in January. For a pharmaceutical company, regulatory compliance is critical to maintaining trust with distributors and healthcare providers. The incident may pressure PMC to invest in tighter supply chain oversight, potentially increasing costs. However, the company’s stable earnings profile (VND 80-84 billion net profit annually) suggests the financial impact of this recall is likely manageable. The stock’s low liquidity amplifies price sensitivity to such news.

What to Watch

• Completion of the recall and any further regulatory actions by the Drug Administration.
• PMC’s Q2 2026 earnings report for any impact on revenue or provisions for recall costs.
• Any additional quality-related fines or sanctions from the Ministry of Health.
• Trading volume and price action of PMC stock, particularly if liquidity improves.
• Management commentary on quality control enhancements in upcoming shareholder communications.